secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001575872-23-000144
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital SPAC to merge with Longevity Biomedical in deal valued at $128M, listing as LBIO
--------------------------------------------------------------------------------

- Merger consideration of $128M payable in shares of New PubCo common stock at $10.00 per share.
- Combined company will be named Longevity Biomedical, Inc.; common stock expected to list on Nasdaq under ticker LBIO.
- Transaction includes concurrent acquisitions of Cerevast Medical, Aegeria Soft Tissue, and Novokera by Longevity.
- Sponsor (Denali Capital Global Investments) and largest Longevity stockholder entered voting/support agreements.
- Closing conditions include at least $30M unrestricted cash proceeds remaining after redemptions and expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000157587223000144/0001575872-23-000144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000157587223000144/deca-20230125.htm
  HTML page:      https://secwatch.observer/filing/0001575872-23-000144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer